knowledge -WSS

knowledge

author：explore 2025-10-02 18:05:50 - browse：72

1:43Traders work on the floor of the New York Stock Exchange on July 12, 2023 in New York City.Spencer Platt/Getty Images

As long-standing recession alarms continue to blare from some forecasters, investors don’t appear to hear them.

The S&P 500 this year, when excluding the ten largest companies, stands at single-digit gains.

Looking ahead, Agati and Moya said they expect the stock market to decline over the remainder of the year, ending 2023 with positive but modest returns. The full economic cooling-off effects of central bank rate hikes have yet to take hold, they said, adding that inflation may not return to normal levels as soon as investors hope.

"The rally will stall out here," Moya said.

MORE: US economy 'quite resilient,' Fed Chair Jerome Powell says

Stoltzfus, however, said there's a "good chance" the stock market will end the year higher than it currently stands.

"We have maintained a fairly bullish posture," he said. "Where the market is trading right now would suggest to us that it has further to go this year."

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： What we owe ALS patients — and why one company fell short

WSS

Chemotherapy shortages won’t get better under Biden’s latest plan

Pregnancy discrimination could be enabled by AI

Chemotherapy shortages won’t get better under Biden’s latest plan

What we owe ALS patients — and why one company fell short

What will Novo Nordisk's VC do with its influx of cash?

Roche to buy Carmot Therapeutics, developer of obesity drugs

hotspot

knowledge

MORE: US economy 'quite resilient,' Fed Chair Jerome Powell says

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

The Karikó problem: Lessons for funding basic research

Malaria cases in Florida and Texas: Here’s what you need to know

Congress extends some pandemic preparedness programs

Trump demands the U.S. pay no more for drugs than other countries … again

SCOTUS to consider access to abortion pill mifepristone

Novavax promises a turnaround & Lilly roils the obesity market

Pfizer plans to depart BIO

How one medical school became remarkably diverse

Why sickle cell disease is getting the first CRISPR treatment

focus

The United States is paying nearly triple for new Covid vaccines

Study points to new risk in gene therapy death of Terry Horgan

Lawsuit highlights wrinkle for disputes over surprise medical bills

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

AI models in health care face new federal disclosure requirements

The United States is paying nearly triple for new Covid vaccines

hotspot

focus

explore

leisure time